Aeovian Pharmaceuticals
Novel small-molecule therapeutics that selectively modulate the mTORC1 signaling pathway
- Sector
- Biotech
- Headquarters
- Berkeley, CA
- Founded
- 2012
- Latest Form D
- $55M, Dec 2025
- Total capital
- $125M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $125M
- 4 Form D · last Dec 2025
- 10 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 6
- 27 pending · first 2021
- Rank in peer group#245 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 4th filing$55M
- Private capital raisedForm D · SEC · 3rd filing$50.4M
- Private capital raisedForm D · SEC · 2nd filing$18.8M
- Private capital raisedForm D · SEC · 1st filing$786K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#245 · top 17%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Stelios TzannisResearcherExecutive Officer, DirectorLinked by 4 patents
- John J. KincaidResearcherExecutive OfficerLinked by 2 patents
- Allison J. HulmeExecutive Officer, DirectorNamed in SEC Form D filings
- Ben ZadikExecutive OfficerNamed in SEC Form D filings
- Davis J. RymanExecutive OfficerNamed in SEC Form D filings
- Jens EcksteinDirectorNamed in SEC Form D filings
Show all 17 people
- Justin J. GoverDirectorNamed in SEC Form D filings
- Lars C. EkmDirectorNamed in SEC Form D filings
- Lars J. EkmanDirectorNamed in SEC Form D filings
- Matthew J. PlunkettExecutive OfficerNamed in SEC Form D filings
- Micah J. ZajicExecutive OfficerNamed in SEC Form D filings
- Michael PowellDirectorNamed in SEC Form D filings
- Nils J. ReggeDirectorNamed in SEC Form D filings
- Richard GasterDirectorNamed in SEC Form D filings
- Themasap J. KhanDirectorNamed in SEC Form D filings
- William J. GreeneDirectorNamed in SEC Form D filings
- Youssef J. BennaniDirectorNamed in SEC Form D filings
What it has protected
USPTO · 6 granted of 33- PendingMtorc Modulators And Uses ThereofUSPTOApplication 19422908
- PendingTricyclic Fused Imidazole Compounds As CD38 Modulators And Uses ThereofUSPTOApplication 19366111
- GrantedMtorc Modulators And Uses ThereofUSPTOUS 12,565,505
Show all 33 patent records
- Mtorc Modulators And Uses ThereofSep 10, 2026 · Application 19422908Pending
- Tricyclic Fused Imidazole Compounds As CD38 Modulators And Uses ThereofMay 21, 2026 · Application 19366111Pending
- Mtorc Modulators And Uses ThereofMar 3, 2026 · US 12,565,505Granted
- CD38 Modulators And Uses ThereofOct 23, 2025 · Application 18960209Pending
- Macrocyclic Substituted Piperidines As MTORC1 Modulators And Uses ThereofJan 4, 2024 · Application 18180517Pending
- MTORC1 Modulators And Uses ThereofOct 19, 2023 · Application 18157224Pending
- Mtorc Modulators And Uses ThereofJul 18, 2023 · US 11,702,429Granted
- MTORC1 Modulators And Uses ThereofApr 25, 2023 · US 11,634,432Granted
- MTORC1 Modulators And Uses ThereofMar 14, 2023 · US 11,603,377Granted
- Mtorc Modulators And Uses ThereofJan 25, 2022 · US 11,230,557Granted
- Mtorc Modulators And Uses ThereofJun 1, 2021 · US 11,021,492Granted
- MTORC1 Modulators And Uses ThereofApplication PCTUS2021042644Pending
- MTORC1 Modulators And Uses ThereofApplication PCTUS2021024536Pending
- MTORC1 Modulators And Uses ThereofApplication 63054763Pending
- MTORC1 Modulators And Uses ThereofApplication 63054768Pending
- MTORC1 Modulators And Uses ThereofApplication 63054762Pending
- MTORC1 Modulators And Uses ThereofApplication 63054767Pending
- MTORC1 Modulators And Uses ThereofApplication 63019176Pending
- MTORC1 Modulators And Uses ThereofApplication 63001144Pending
- MTORC1 Modulators And Uses ThereofApplication 63001177Pending
- MTORC1 Modulators And Uses ThereofApplication 63001187Pending
- Combo Therapies Using GLP-1 And CD38 ModulatorsApplication PCTUS2025056697Pending
- Mtorc Modulators And Uses ThereofApplication PCTUS2020014671Pending
- CD38 Modulators And Uses ThereofApplication PCTUS2025051912Pending
- Combo Therapies Using GLP-1 And CD38 ModulatorsApplication 63723440Pending
- CD38 Modulators And Uses ThereofApplication 63710507Pending
- CD38 Modulators And Uses ThereofApplication PCTUS2024026107Pending
- CD38 Modulators And Uses ThereofApplication 63627213Pending
- CD38 Modulators And Uses ThereofApplication 63578614Pending
- CD38 Modulators And Uses ThereofApplication PCTUS2023067887Pending
- CD38 Modulators And Uses ThereofApplication 63498182Pending
- CD38 Modulators And Uses ThereofApplication 63376647Pending
- CD38 Modulators And Uses ThereofApplication 63348381Pending
Related companies, and why
- BioNTech SESimilar federal contract value in Biotech · null in contracts
- Attralus, Inc.Similar federal contract value in Biotech · null in contracts
- NEONC TECHNOLOGIES HOLDINGS, INC.Similar federal contract value in Biotech · null in contracts
- ILiAD BiotechnologiesSimilar federal contract value in Biotech · null in contracts
- Acrivon Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Circle Pharma, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .